Colistin-glycopeptide combinations against multidrug-resistant Acinetobacter baumannii in a mouse model of pneumonia

Future Microbiol. 2019 May:14:581-586. doi: 10.2217/fmb-2019-0022. Epub 2019 Jun 7.

Abstract

Aim: To assess the effect of colistin-glycopeptide combination against a multidrug-resistant strain of Acinetobacter baumannii. Materials & methods: We used in vitro procedures (Etest method, checkerboard test and kill-time assays) and a mouse model of a carbapenem-resistant A. baumannii pneumonia. Results: The colistin-teicoplanin combination allowed a 74% increase of the survival in the mouse model within the 4 days following bacterial inoculation as compared with saline or colistin alone (p = 0.06). Concurrently, the colistin-vancomycin combination presented a similar efficacy as compared with saline or colistin alone in the mouse model. Conclusion: According to those preliminary results, using the colistin-teicoplanin combination in therapeutic deadlocks encountered in certain multiresistant A. baumannii pneumonia could be envisaged if the results are confirmed.

Keywords: antimicrobial combinations; colistin; experimental infections; glycopeptides; multidrug resistance; pneumonia; teicoplanin; vancomycin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acinetobacter Infections / drug therapy*
  • Acinetobacter Infections / microbiology
  • Acinetobacter baumannii / drug effects*
  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Colistin / pharmacology*
  • Disease Models, Animal
  • Drug Combinations
  • Drug Resistance, Multiple, Bacterial / drug effects*
  • Drug Synergism
  • Female
  • Glycopeptides / pharmacology*
  • Mice
  • Mice, Inbred C3H
  • Microbial Sensitivity Tests
  • Pneumonia / drug therapy*
  • Survival Rate
  • Teicoplanin / pharmacology
  • Vancomycin / pharmacology

Substances

  • Anti-Bacterial Agents
  • Drug Combinations
  • Glycopeptides
  • Teicoplanin
  • Vancomycin
  • Colistin